Summary
The pharmacokinetics of amsacrine have been studied after the first and third infusions (200 mg·m-2) in 10 patients receiving combined chemotherapy for the treatment of acute myelogenous leukaemia (AML). Postinfusion amsacrine elimination was best described by a biexponential expression with a mean t1/2α of 0.8 h and a terminal t1/2β of 5.3 h. After the third infusion there was a significant reduction (P<0.05) in the plasma clearance (Cl) and a prolongation of the terminal half-life (t1/2β) (P<0.01), but no change in the initial half-life (T1/2α) or volume of distribution (Vd). No significant overall changes were recorded in any of the biochemical indices of renal or hepatic function between the first and third infusions, but the patient who exhibited the largest reduction in Cl showed a marked increase in AST levels and a reduction in albumin concentration. Two distinct groups were apparent after the first infusion, patients with a Cl>294 and those with a Cl<208 ml·h-1·kg-1. The latter patients were significantly older (P<0.05), and four of the five had subnormal albumin concentrations. Urinary determination of amsacrine indicated that renal elimination plays a minor role in the total clearance of this drug. Amsacrine was also found to be highly bound to plasma proteins (96.4%–97.7%), but changes in binding were not responsible for the reduced Cl and prolonged t1/2β observed between the first and third infusions. We suggest that the elimination of amsacrine may be susceptible to small changes in hepatic function, perhaps due to the high amsacrine concentrations (5–18 μmol·l-1) achieved with this regimen, which may be approaching saturation of the capacity for hepatic elimination.
Similar content being viewed by others
References
Arlin ZA, Flomenberg N, Gee TS, Kempin SJ, Dellaquila C, Mertelsmann R, Straus DJ, Young CW, Clarkson BD (1981) Treatment of acute leukaemia in relapse with 4′-(9-acridinylamino) methanesulphon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine. Cancer Clin Trials 4: 317
Arlin ZA, Gee TS, Mertelsmann R, Kempin SJ, Reich LM, Straus DJ, Miggins C, Clarkson BD (1983) Randomized trial of 4′(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside (ARA-C) and thioguanine (TG) vs daunorubicin with ARA-C and TG in adults with acute non-lymphoblastic leukaemia (ANLL). In: Amsacrine. Current perspectives and clinical results with a new anti-cancer agent. Communications Media for Education, New Jersey, p 977
Atwell GJ, Cain BF, Seelye RN (1972) Potential Antitumour agents. 12. 9-Anilinoacridines. J Med Chem 15: 611
Cain BF, Atwell GJ (1974) The experimental antitumour properties of three congeners of the acridylmethane-sulphonanilide (AMSA) series. Eur J Cancer 10: 539
Cain BF, Seelye RN, Atwell GJ (1974) Potential Antitumour agents. 14. Acridylmethanesulphonanilides. J Med Chem 17: 922
Cysyk RL, Shoemaker D, Adamson RH (1971) The pharmacological disposition of 4′-(9-acridinylamino) methanesulfon-m-anisidide in mice and rats. Drug Metab Dispos 5: 579
Gibaldi M, Perrier D (1975) In: Pharmacokinetics. Marcel Dekker, New York, p 69
Goldman A, Malpas JS (1982) Phase I and II study of AMSA in childhood tumours. Cancer Chemother Pharmacol 9: 53
Hall SW, Friedman J, Legha SS, Benjamin RS, Gutterman JU, Loo TL (1983) Human pharmacokinetics of a new acridine derivative, 4′-(9-acridinylamino) methanesulfon-m-anisidide (NSC 249992). Cancer Res 43: 3422
Jacquillat C (1983) Amsacrine in acute leukaemia: In: Amsacrine. Current perspectives and clinical results with a new anti-cancer agent. Communication Media for Education, New Jersey, p 41
Jurlina JL, Paxton JW (1983) A high-performance liquid chromatographic method for the determination of 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in plasma. J Chromatogr 276: 367
Legha SS, Keating MJ, Zander AA, McCredie KB, Bodey GP, Freireich EG (1980) 4′(Acridinylamino) methanesulfon-m-anisidide (AMSA): A new drug effective in the treatment of adult acute leukaemia. Ann Intern Med 93: 17
Legha SS, Keating MJ, McCredie KB, Bodey GP (1982) Evatuation of AMSA in previously treated patients with acute leukaemia: Results of therapy in 109 adults. Blood 60: 484
Lima JJ, Boudoulas H, Blanford M (1981) Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics. J Pharmacol Exp Ther 219: 741
Malspeis L, Khan MN, Blat HB (1979) HPLC determination of 4′-(9-acridinylamino)methanesulfon-m-anisidide (M-AMSA) (NSC 249992) in the plasma of a patient with hepatic dysfunction. Proc Am Assoc Cancer Res 20: C384 (abstract 383)
Metzler CM (1969) NONLIN. A computer program for parameter estimation in non-linear situations. Upjohn (Biostatistics Dept), Kalamazoo
Micetich KC, Zwelling LA, Gormley P, Young RC (1982) Phase I–II study ofm-AMSA administered as a continuous infusion. Cancer Treat Rep 66: 1813
Paxton JW, Jurlina JL (1984) Determination of the anti cancer drug amsacrine in biological fluids by HPLC. In: Methodological surveys in biochemistry and analysis, vol 14. Reid E, Wilson ID (eds) Drug determination for therapeutic and forensic appraisals. Plenum Press, London (in press)
Rivera G, Evans WE, Dahl GV, Yee C, Pratt CB (1980) Phase I clinical and pharmacokinetic study of 4′-(9-acridinylamino)methanesulfon-m-anisidide in children with cancer. Cancer Res 40: 4250
Sedman AJ, Wagner JC (1974) AUTOAN. A decision-making pharmacokinetic computer programme. Publication Distribution Service, University of Michigan Medical Center, Ann Arbor
Staubus A, Neidhart J, Young D, Malspeis L (1980) Pharmacokinetics ofm-AMSA (NSC 249992) in humans. Proc Am Assoc Cancer Res 21: 198 (abstract 793)
Tan CTC, Hancock C, Steiherz PG, Steinherz LJ, Sorell M, Chan KW, Mondora A, Miller DR (1982) Phase II study of 4′-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukaemia and lymphoma. Cancer Res 42: 1579
Van Echo DA, Chiuten DF, Gormley PE, Lichtenfield JL, Scotlock M, Wiernik P (1979) Phase I clinical and pharmacological study of 4′(9-acrinylamino)methanesulfon-m-anisidide using an intermittent by-weekly schedule. Cancer Res 39: 3881
Von Hoff DD, Howser D, Gormley PE, Bender RA, Glaubiger D, Levine AS, Young RC (178) Phase I study of methanesulfon-amide,N-[4-(9- acidinylamino)-3-methoxy phenyl] (m-AMSA) using a single-dose schedule. Cancer Treat Rep 62: 1421
Weick JK, Jones SE, Ryan DH (1983) Phase II study of amsacrine (m-AMSA) in advanced lymphomas: A Southwest Oncology Group Study. Cancer Treat Rep 67: 489
Winton EF, Hearn EB, Vogler WR, Johnson L, Logan T, Raney M (1983) Amsacrine in refractory adult acute leukaemia: a pilot study of the Southeastern Cancer Study Group. Cancer Treat Rep 67: 977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jurlina, J.L., Varcoe, A.R. & Paxton, J.W. Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. Cancer Chemother. Pharmacol. 14, 21–25 (1985). https://doi.org/10.1007/BF00552719
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00552719